05 October 2022: Clinical Research
Performance of Xpert MTB/RIF for Diagnosis of Tuberculosis in HIV-Infected People in China: A Retrospective, Single-Center Study
Guiju Gao 1ACDEFG* , Chunyu Zhu 2BCDEF* , Yingchu Liu 3BCDEF* , Siyuan Yang 4AB* , Jiang Xiao 1ACD , Hongxin Zhao 1CDF , Di Yang 1CDF , Hongyuan Liang 1BCF , Fang Wang 1BDF , Liang Wu 1BCF , Fujie Zhang 1ACEF , Liang Ni 1CFDOI: 10.12659/MSM.937264
Med Sci Monit 2022; 28:e937264
Table 3 Sensitivity and specificity of Xpert in different specimens.
| N (%) | Xpert-positive | Sensitivity (95% CI) | Specificity (95% CI) | |
|---|---|---|---|---|
| PTB cases 145 | ||||
| Sputum | 25 (18.2%) | 12 (84.0%) | 80.0 (29.8–98.9) | 71.4. (47.6–87.8) |
| BALF | 66 (48.1%) | 9 (28.7%) | 100.0 (19.7–100.0) | 81.2 (69.1–89.5) |
| EPTB cases 32 | ||||
| CSF | 20 (62.5%) | 0 (0%) | N/A* | 95.0 (73.1–99.7) |
| Ascitic fluid | 1 (3.1%) | 1 (100%) | NA | N/A |
| Urine | 2 (3.2%) | 1 (50.0%) | N/A | 50.0 (2.6–97.3) |
| Pleural fluid | 3 (9.3%) | 2 (66.6%) | N/A | 66.6 (12.5–98.2) |
| BALF – bronchoalveolar lavage fluid; CSF – cerebrospinal fluid; NA – not available. * If fewer than 3 positive cases are tested, no calculation will be made. | ||||